Structural characterization and pharmacodynamic effects of an orally active 11β-hydroxysteroid dehydrogenase type 1 inhibitor

Chemical Biology and Drug Design

Volumn 71, Issue 1, 2008, Pages 36-44

  Hale, Clarence ^a   Véniant, Murielle ^a   Wang, Zhulun ^a   Chen, Michelle ^a   McCormick, Jocelyn ^a   Cupples, Rod ^a   Hickman, Dean ^a   Min, Xiaoshan ^a   Sudom, Athena ^a   Xu, Haoda ^a   Matsumoto, Guy ^a   Fotsch, Christopher ^a   St Jean Jr , David J ^a   Wang, Minghan ^a  

^a AMGEN INC   (United States)

Author keywords

11 hydroxysteroid dehydrogenase; Glucocorticoids; Hypothalamic pituitary adrenal axis; Pharmacodynamic

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2 [1 (2 FLUOROPHENYL)ETHYLAMINO] 5 METHYL 5 (TRIFLUOROMETHYL)THIAZOL 4(5H) ONE; ALANINE; ENZYME INHIBITOR; HYDROCORTISONE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TYROSINE; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CHO CELL; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG STRUCTURE; HYDROGEN BOND; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; IC 50; MALE; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ADIPOSE TISSUE; ADMINISTRATION, ORAL; ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN STRUCTURE, TERTIARY; THIAZOLES;

MUS;

EID: 37849041637     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2007.00603.x     Document Type: Article

References (27)

1. Wang M. (2005) The role of glucocorticoid action in the pathophysiology of the metabolic syndrome. Nutr Metab 2 : 3.
2. Ozols J. (1995) Lumenal orientation and post-translational modifications of the liver microsomal 11β-hydroxysteroid dehydrogenase. J Biol Chem 278 : 2305 2312.
3. Odermatt A., Arnold P., Stauffer A., Frey B.M., Frey F.J. (1999) The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 274 : 28762 28770.
4. Arnaldi G., Angeli A., Atkinson A.B., Bertagna X., Cavagnini F., Chrousos G.P., Fava G.A., et al. (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88 : 5593 5602.
5. Rask E., Olsson T., Soderberg S., Andrew R., Livingstone D.E., Johnson O., Walker B.R. (2001) Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 86 : 1418 1421.
6. Kannisto K., Pietilainen K.H., Ehrenborg E., Rissanen A., Kaprio J., Hamsten A., Yki-Jarvinen H. (2004) Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 89 : 4414 4421.
7. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., Flier J.S. (2001) A transgenic model of visceral obesity and the metabolic syndrome. Science 294 : 2166 2170.
8. Kotelevtsev Y., Holmes M.C., Burchell A., Houston P.M., Schmoll D., Jamieson P., Best R., Brown R., Edwards C.R., Seckl J.R., Mullins J.J. (1997) 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 94 : 14924 14929.
9. Morton N.M., Paterson J.M., Masuzaki H., Holmes M.C., Staels B., Fievet C., Walker B.R., Flier J.S., Mullins J.J., Seckl J.R. (2004) Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 53 : 931 938.
10. Kershaw E.E., Morton N.M., Dhillon H., Ramage L., Seckl J.R., Flier J.S. (2005) Adipocyte-specific glucocorticoid inactivation protects against diet-induced obesity. Diabetes 54 : 1023 1031.
11. Alberts P., Engblom L., Edling N., Forsgren M., Klingstrom G., Larsson C., Ronquist-Nii Y., Ohman B., Abrahmsen L. (2002) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 45 : 1528 1532.
12. Alberts P., Nilsson C., Selen G., Engblom L.O., Edling N.H., Norling S., Klingstrom G., et al. (2003) Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 144 : 4755 4762.
13. Hermanowski-Vosatka A., Balkovec J.M., Cheng K., Chen H.Y., Hernandez M., Koo G.C., Le Grand C.B., et al. (2005) 11β-HSD1 inhibition ameliorates the metabolic syndrome and prevents progression of atherosclerosis in mice. J Exp Med 202 : 517 527.
14. Wang M. (2006) Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 for the treatment of metabolic syndrome. Curr Opin Investig Drugs 7 : 319 323.
15. Kim K.W., Wang Z., Busby J., Tsuruda T., Chen M., Hale C., Castro V.M., Svensson S., Nybo R., Xiong F., Wang M. (2006) The role of tyrosine 177 in human 11β-hydroxysteroid dehydrogenase type 1 in substrate and inhibitor binding: an unlikely hydrogen bond donor for the substrate. Biochim Biophys Acta 1764 : 824 830.
16. Kim K.W., Wang Z., Busby J., Tsuruda T., Chen M., Hale C., Castro V.M., Svensson S., Nybo R., Xiong F., Wang M. (2007) The selectivity of tyrosine 280 of human 11β-hydroxysteroid dehydrogenase type 1 in inhibitor binding. FEBS Lett 581 : 995 999.
17. Sorensen B., Winn M., Rohde J., Shuai Q., Wang J., Fung S., Monzon K., et al. (2007) Adamantane sulfone and sulfonamide 11-β-HSD1 inhibitors. Bioorg Med Chem Lett 17 : 527 532.
18. Patel J.R., Shuai Q., Dinges J., Winn M., Pliushchev M., Fung S., Monzon K., et al. (2007) Discovery of adamantane ethers as inhibitors of 11β-HSD-1: synthesis and biological evaluation. Bioorg Med Chem Lett 17 : 750 755.
19. St. Jean D.J. Jr., Yuan C., Bercot E.A., Chen M., Fretland J., Hale C., Hungate R.W., Komorowski R., Véniant M., Wang M., Zhang X., Fotsch C. (2007) 2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11β-hydroxysteriod dehydrogenase type 1. J Med Chem 50 : 429 432.
20. Hosfield D.J., Wu Y., Skene R.J., Hilgers M., Jennings A., Snell G.P., Aertgeerts K. (2005) Conformational flexibility in crystal structures of human 11β-HSD1 provide insights into glucocorticoid interconversion and enzyme regulation. J Biol Chem 280 : 4639 4648.
21. Leslie A.G.W. (1992) Recent changes to the MOSFLM package for processing film and image plate data. CCP4 and ESF-EACMB Newsletter on Protein Crystallography, Number 26 England : SERC Laboratory, Daresbury, Warrington WA 4AD.
22. Collaborative Computational Project, No. 4 1994) The CCP4 Suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50 : 760 763.
23. Emsley P., Cowtan K. (2004) COOT: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 60 : 2126 2132.
24. Zhang J., Osslund T.D., Plant M.H., Clogston C.L., Nybo R.E., Xiong F., Delaney J.M., Jordan S.R. (2005) Crystal structure of murine 11β-hydroxysteroid dehydrogenase 1: an important therapeutic target for diabetes. Biochemistry 44 : 6948 6957.
25. Barf T., Vallgarda J., Emond R., Haggstrom C., Kurz G., Nygren A., Larwood V., et al. (2002) Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs: discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 45 : 3813 3815.
26. Chrousos G.P. (2004) Is 11β-hydroxysteroid dehydrogenase type 1 a good therapeutic target for blockade of glucocorticoid actions? Proc Natl Acad Sci USA 101 : 6329 6330.
27. von Geldern T.W., Tu N., Kym P.R., Link J.T., Jae H.S., Lai C., Apelqvist T., et al. (2004) Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem 47 : 4213 4230.